TDC
BDSX icon

Thompson Davis & Co’s Biodesix BDSX Stock Holding History

Thompson Davis & Co’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Sell
11,350
-400
-3% -$5.93K 0.15% 120
2026
Q1 		$170K Buy
+11,750
New +$146K 0.11% 120

Other funds holding BDSX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TAM
Telemark Asset Management Boston, Massachusetts $1.38B AUM 71.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Thompson Davis & Co's BDSX Position: Q2 2026 in Review

Thompson Davis & Co reduced its Biodesix (BDSX) stake by 3.4% in Q2 2026, selling an estimated $5.93K and leaving 11,350 shares worth $256K. The position accounts for 0.15% of the portfolio, ranked #120.

Thompson Davis & Co first reported a position in BDSX in Q1 2026 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold BDSX as of Q2 2026.

  • Thompson Davis & Co held 11,350 shares of Biodesix worth $256K as of Q2 2026.
  • Thompson Davis & Co sold 400 Biodesix shares in Q2 2026, an estimated $5.93K.
  • Biodesix made up 0.15% of Thompson Davis & Co's portfolio in Q2 2026, its #120 holding.
  • Thompson Davis & Co first reported a position in Biodesix in Q1 2026 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Biodesix as of Q2 2026.

Based on Thompson Davis & Co's 13F filing for Q2 2026, filed 29 Jul 2026.